myocarditis and heart failure: diagnosis, prognosis and ... · treatment 24th annual heart failure...
TRANSCRIPT
![Page 1: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/1.jpg)
Leslie T. Cooper, Jr., MD
Myocarditis and Heart Failure: Diagnosis, Prognosis and
Treatment
24th Annual Heart Failure 2020:
an Update on Therapy
August 1st, 2020
![Page 2: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/2.jpg)
DISCLOSURE
Relevant Financial Relationship(s)
None
Off Label Usage
None
![Page 3: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/3.jpg)
Outline
• Viral or Lymphocytic Myocarditis-
New definitions, diagnosis and management
• Giant Cell, Hypersensitivity, and Checkpoint
inhibitor myocarditis, Cardiac Sarcoidosis
![Page 4: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/4.jpg)
Bozkurt, B et al Circulation 2016 Caforio, EHJ 2013
![Page 5: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/5.jpg)
Myocarditis and Cardiomyopathy # Deaths and Death Rate /100,000
1990-2015
JACC, Nov 29th 2016
Lancet November 10th, 2018
1.37M myocarditis cases in 2019
343,000
![Page 6: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/6.jpg)
Myocarditis Clinical Presentations
• Myopericarditis/MINOCA
• Sudden Death
• Acute Dilated Cardiomyopathy
• Chronic Dilated Cardiomyopathy
![Page 7: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/7.jpg)
Acute Myocarditis EKG
CP1291921-1
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
QRS > 120ms, high degree heart block
Predict poor outcome
![Page 8: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/8.jpg)
Mouse model of
CVB Myocarditis
Marholdt, H, etal. Circulation 2004
Epicardial-Mid Wall
Myocarditis: MRI and Histology
Fairweather, DL, Cooper, LT, et al
![Page 9: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/9.jpg)
European Heart Journal, Volume 40, Issue Supplement_1, October 2019, ehz748.0565,
https://doi.org/10.1093/eurheartj/ehz748.0565
Detection Rate of Myocarditis
by MRI
![Page 10: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/10.jpg)
2009 versus 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis
Leutkens, JA et al Radiology: Cardiothoracic Imaging 2019: 1(3)
![Page 11: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/11.jpg)
Time Course of Native T1 and T2 Recovery in Acute
Myocarditis
Hinojar R et al. JACC Cardiovasc Imaging. 2015
Hinojar R J Cardiovasc Magn Reson. BioMed Central; 2014
![Page 12: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/12.jpg)
Histologic “Dallas” Criteria
Aertz, et al Am J Pathol 1986
Sampling error, Variation in interpretation,
Low sensitivity, Lack of correlation with outcome
Baughman, K, Circulation 2006
![Page 13: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/13.jpg)
Immuostains for the Diagnosis of Myocarditis
Nakayama et al EJHF 2017
CD3 CD68 CD163
![Page 14: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/14.jpg)
Number of Inflammatory Cells Predicts Outcome in Myocarditis
Nakayama et al EJHF 2017
CD3-T cells CD68- Macrophages
![Page 15: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/15.jpg)
Innsbruck and Maastricht
Inflammatory Cardiomyopathy Registry
Circ Heart Fail. 2018 ≥14 infiltrating inflammatory cells/mm2
AZA + Pred
↑ survival
![Page 16: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/16.jpg)
• 374 patients with suspected myocarditis
• Chest pain 95%
• Age 35, 73% male; LVEF 62%
• Median FU 4.3 years
• Events: 26/374.
ITAMY Study Ten Center Italian Registry
2006-2013
Aquaro, et al JACC 2017
![Page 17: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/17.jpg)
Anteroseptal Pattern on MRI Increased risk of MACE
Aquaro, et al JACC 2017
5 yr event probability 0.36 in AS group
![Page 18: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/18.jpg)
• 670 patients with suspected myocarditis
• Chest pain 52% (LV dysfunction/ dyspnea 30%; Rhythm problems 18%)
• Age 47, 59% male; 13% QRS>120 ms
• All had MRI -294 with DGE
• Median FU 4.7 years
Brigham and Women’s Hospital MRI Case Series
2002-2015
Grani, C et al JACC 2017
![Page 19: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/19.jpg)
DGE on CMR associated with greater risk of MACE
Grani, C et al JACC 2017
![Page 20: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/20.jpg)
Annualized Risk of Death varies with LVEF and DGE
Grani, C et al JACC 2017
![Page 21: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/21.jpg)
Ventricular Arrhythmias and Sudden Cardiac Death in Lymphocytic
Myocarditis
• Risk 0 after resolution of DGE
• Risk increased if DGE increases
Peretto. Et al, 25 (9) March 10th 2020
Cooper, LT JACC 25 (9) March 10th 2020
![Page 22: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/22.jpg)
Kociol, R, Cooper, LT et al
Circulation February 2020
![Page 23: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/23.jpg)
58 yo Woman admitted October 23, 2019
![Page 24: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/24.jpg)
ECG Low QRS voltage due to myocardial edema An injury current with ST elevations in contiguous leads Pericarditis with PR segment changes may also be present Troponin is almost always elevated in 1st week* Echo May show normal LVEDD and left ventricular hypertrophy
Fulminant Myocarditis Sudden and severe inflammation resulting in myocyte necrosis,
edema, and cardiogenic shock.
![Page 25: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/25.jpg)
Courtesy of Bill Edwards
![Page 26: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/26.jpg)
Algorithm for the Evaluation of Suspected Myocarditis
in the Setting of Unexplained Acute DCM
Bozkurt, et al. Circulation, 2016
Unexplained Acute
Cardiomyopathy*
Required inotropic or mechanical circulatory support,
Mobitz type 2 second degree or higher heart block, sustained
or symptomatic ventricular tachycardia or failure to respond to
guideline based medical management within 1-2 weeks?
Yes-Endomyocardial Biopsy
COR I/LOE B
No-Cardiac MRI
COR 2B/LOE C
*Usually a dilated cardiomyopathy. Fulminant myocarditis may have normal end diastolic diameter with mildly thickened walls. Excluded ischemic, hemodynamic (valvular, hypertensive), metabolic, and toxic causes of cardiomyopathy as indicated clinically.
![Page 27: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/27.jpg)
Survival in Fulminant Versus Nonfulminant Acute Myocarditis n=187
Enrico Ammirati, Circulation August 2017
![Page 28: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/28.jpg)
Mason et al, NEJM. Aug 9th, 1995
No effect of Prednisone + AZA or CSA in LVEF or Survival
![Page 29: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/29.jpg)
JACC, October 2017
![Page 30: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/30.jpg)
Prognosis in Myocarditis Varies by Histology
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
Cooper, et al: N Engl J Med 1997 336:1860-66
Years
Pro
po
rtio
n s
urv
ivin
g
Giant-cell myocarditis
Lymphocytic myocarditis
P<0.0001
![Page 31: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/31.jpg)
When to Suspect Giant Cell Myocarditis
• Rapidly Progressive course
• Failure to Respond to Usual Care
• Ventricular Tachycardia
• High-grade Heart Block
8 Of 28 (29%) screened subjects
in the GCM Trial had GCM
Cooper, LT. et al. Am Ht J 2008
![Page 32: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/32.jpg)
Endomyocardial biopsy before and after OKT3, CSA, Steroid
immunosuppression
Sensitivity of EMB for GCM is 80-85%
![Page 33: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/33.jpg)
Kandolin, R et al Circ HF 2013
GCM survival treated with Multidrug Immunosuppression
![Page 34: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/34.jpg)
Eosinophilic Myocarditis
Brambatti, et al. JACC Nov 7th 2017
![Page 35: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/35.jpg)
Clozapine: Example of Drug Hypersensitivity
• Myocarditis: Up to 1:1000
• 50/213 cases fatal
• 85% occur in first 2 months
of treatment
• Eosinophilia up to 66%
De Berardis, DD et al. Current Drug Safety 2012
Ben m’rad M, et al. Medicine 2009
![Page 36: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/36.jpg)
• Prevalence of Myocarditis 1.14%
• CHB 3; CV shock 3; CV arrest 4 cases
• Overall 46% MACE rate over 102 days
• Median time from treatment 34 days
• Higher dose steroids associated with lower troponin and MACE rates
Checkpoint Inhibitor Myocarditis 8 Centers; n=35
Mahmood, SS JACC 2018
![Page 37: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/37.jpg)
• Cardiotoxicity presents within 2 months with CHF or ventricular arrhythmias. MRI or biopsy
• Start methylprednisolone 1-2 mg/kg
• If deterioration, consider adding abatacept Annals of Oncology 2017
Brahmer, JR et al. J Clin Onc 2018
Insert image of page- Brahmer JR, et al. Management of
immune-related adverse events in patients treated
with immune checkpoint inhibitor therapy: American
Society of Clinical Oncology
clinical practice guideline. J Clin Oncol 2018;36:1714-
1768.
![Page 38: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/38.jpg)
©2012 MFMER
| slide-37
48 year old woman with Complete Heart Block
![Page 39: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/39.jpg)
Birnie, D et al 2014
Algorithm for the
Evaluation of Cardiac
Sarcoidosis
![Page 40: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/40.jpg)
Sites of Cardiac Sarcoidosis at Autopsy
Kandolin 2015
Differential Diagnosis:
ARVC/ALVC
Myocarditis
Other Systemic Causes of
cardiac Inflammation:
eg.GPA
![Page 41: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/41.jpg)
©2012 MFMER
| slide-40
SA
HLA
VLA
13N-NH3 defects and matched 18F-FDG uptake
associated with Cardiac Sarcoidosis
NH3 FDG
![Page 42: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/42.jpg)
Cardiac PET and Prognosis in known or suspected CS
Blankstein, JACC 2014
Chareonthaitawee, P, J Nucl Cardiol. 2017
• Abnormal myocardial perfusion and metabolism had a four-fold increase in the annual rate of ventricular tachycardia or death compared to patients with normal imaging (n= 118)
• SNMMI Position Statement on The Role of PET/CT in Cardiac Sarcoidosis- August 2017
![Page 43: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/43.jpg)
Baseline Following Infliximab
Courtesy of Jukka Lehtonen
FDG PET can follow
Response to Treatment
![Page 44: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/44.jpg)
2020 Summary of Management of Acute/Fulminant Myocarditis
• All- GDMC and hemodynamic support- unloading if possible; avoid sports for 3-6 months.
• GCM- Immunosuppression including cyclosporine or tacrolimus; ATG or Campath, ICD if expected survival > 1 year.
• Checkpoint Inhibitor- Corticosteroids, Abatacept?
• Eosinophilic- Corticosteroids, Mepolizumab?
![Page 46: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/46.jpg)
Randomized Clinical Trials 2020-2022
• IVIG for PVB19 positive Chronic DCM NCT 000659386- Maastrict
• Secukinumab (anti IL-17) for Acute myocarditis -Frankfurt
• Anakinra 100 mg SQ for CPI Myocarditis- until hospital discharge or a maximum of 14 days -Paris
• CASTT- Canadian Sarcoidosis Tx Trial (CHASM-CS; CHIR IRSC- Ottawa Heart)
• eMAP -electrogram biopsy(U Penn; Mayo)
![Page 47: Myocarditis and Heart Failure: Diagnosis, Prognosis and ... · Treatment 24th Annual Heart Failure 2020: an Update on Therapy August 1st, 2020 . DISCLOSURE Relevant Financial Relationship(s)](https://reader033.vdocuments.mx/reader033/viewer/2022042613/5f976cea38638a2e4f022e92/html5/thumbnails/47.jpg)
Cardiac MRI and Biopsy with Sarcoidosis